Xiyang Yanbin, Gao Ju, Ding Mao, Ren Xiaojia, Appleby Brian S, Leverenz James B, Miyagi Masaru, Pillai Jagan A, Perry George, Wang Xinglong
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Institute of Neuroscience, Kunming Medical University, Kunming, China.
J Alzheimers Dis. 2024 Dec;102(4):1074-1083. doi: 10.1177/13872877241295403. Epub 2024 Nov 25.
Rapidly progressive Alzheimer's disease (rpAD) is a clinical subtype distinguished by its rapid cognitive decline and shorter disease duration. rpAD, like typical AD (tAD), is characterized by underlying neuropathology of amyloid plaques and neurofibrillary tangles. There is early evidence that the composition of amyloid plaques could vary between the rpAD and tAD. Differences in tau pathology between rpAD and tAD are also of interest. Additionally, mitochondrial dysfunction is a key early-stage change in tAD but has not yet been evaluated in rpAD.
To deepen our understanding of the underlying pathophysiological processes specific to rpAD, we explore potential changes in tau pathology and mitochondrial dysfunction in rpAD compared to tAD.
We performed immunohistochemical and immunoblot analyses of tau, phosphorylated tau, and key regulators of mitochondrial dynamics and bioenergetics in postmortem human temporal cortex tissues obtained from patients diagnosed with tAD or rpAD, and tissues from age-matched normal subjects.
tAD was characterized by significant tau phosphorylation at the PHF1 epitope. Unexpectedly, rpAD showed milder PHF1 tau phosphorylation, similar to that of age-matched controls. Despite these differences in tau pathology, both tAD and rpAD exhibited a significant decrease in the key regulators of mitochondrial dynamics and bioenergetics compared to controls. However, the decline in mitochondrial dynamics regulators was more pronounced in rpAD.
These findings suggest divergent pathological processes between tAD and rpAD, specifically in terms of tau pathology and mitochondrial dynamic abnormalities, which underscore the necessity for different approaches to understand and potentially treat various AD subtypes.
快速进展性阿尔茨海默病(rpAD)是一种临床亚型,其特点是认知功能快速衰退且病程较短。rpAD与典型阿尔茨海默病(tAD)一样,具有淀粉样斑块和神经原纤维缠结的潜在神经病理学特征。早期有证据表明,rpAD和tAD之间淀粉样斑块的组成可能存在差异。rpAD和tAD之间tau病理学的差异也备受关注。此外,线粒体功能障碍是tAD的关键早期变化,但尚未在rpAD中进行评估。
为了加深我们对rpAD特有的潜在病理生理过程的理解,我们探讨了与tAD相比,rpAD中tau病理学和线粒体功能障碍的潜在变化。
我们对从诊断为tAD或rpAD的患者以及年龄匹配的正常受试者的尸检人类颞叶皮质组织中获取的tau、磷酸化tau以及线粒体动力学和生物能量学的关键调节因子进行了免疫组织化学和免疫印迹分析。
tAD的特征是在PHF1表位处tau发生显著磷酸化。出乎意料的是,rpAD显示出较轻的PHF1 tau磷酸化,与年龄匹配的对照组相似。尽管tau病理学存在这些差异,但与对照组相比,tAD和rpAD中线粒体动力学和生物能量学的关键调节因子均显著减少。然而,rpAD中线粒体动力学调节因子的下降更为明显。
这些发现表明tAD和rpAD之间存在不同的病理过程,特别是在tau病理学和线粒体动态异常方面,这强调了采用不同方法来理解和潜在治疗各种AD亚型的必要性。